



## **FOR IMMEDIATE RELEASE**

### **Contacts:**

#### **For Ohmx Corporation:**

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@Ohmx.com

## Ohmx Announces Formation of Scientific Advisory Board

**Evanston, IL, January 31<sup>st</sup>, 2007** – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for home monitoring of chronic diseases, is pleased to announce the latest additions to its Scientific Advisory Board. This press release is an update to an earlier press release (04-01-05) that announced the foundation of the Scientific Advisory Board.

The Advisory Board comprises experts from various disciplines who will provide direction and insight for future product innovations and strategies. "It's an honor to have such distinguished members on our Scientific Advisory Board who will bring significant expertise and breadth of knowledge to Ohmx," said Thomas Meade, Founder, President and CEO of Ohmx.

Members of the Scientific Advisory Board include:

**Harry B. Gray, Ph.D.** is the Arnold O. Beckman Professor of Chemistry and the Founding Director of the Beckman Institute at the California Institute of Technology. Dr. Gray is the 2004 recipient of the Wolf Foundation Prize in chemistry and widely is recognized for his pioneering work in long-range electron transfer processes in proteins. Dr. Gray has made significant contributions to chemistry, including authoring over 650 papers and 17 books. Dr. Gray holds a B.S. in chemistry from Western Kentucky University and a Ph.D. in inorganic chemistry from Northwestern University and is a Member of the National Academy of Sciences.

**Gary F. Blackburn, Ph.D.** is Director of Research and Technology at Clinical Micro Sensors, a Motorola company. Dr. Blackburn has contributed significantly in the areas of in chemical sensors employing field-effect transistors, catalytic antibodies, electrodes modified with membrane-mimetic thin films, electrogenerated chemiluminescence (ECL), and electron transfer at electrodes modified with self-assembled monolayers. Previously, he served as Director of Research at IGEN International and Director of Technology Management at Boehringer Mannheim Diagnostics and Roche Diagnostics. Dr. Blackburn has many publications in the field of diagnostic applications of chemical sensors and holds 31 U.S. and EP patents. He holds a B.S. in chemistry from the University of Utah, an M.S. and a Ph.D. in bioengineering also from the University of Utah and completed his postdoctoral training at Cornell University.

**Thomas O'Halloran, Ph.D.** is the Morrison Professor of Chemistry and Biochemistry, Molecular Biology and Cell Biology at Northwestern University. He

was elected Chair of the Bioinorganic Division of the American Chemical Society and also served as Chair of a NIH Study Section (BMT) from 1999-2001. He also serves on an advisory board to the United States Department of Energy Biological Sciences Directorate (2001-2004). He holds a B.S. and an M.S. in chemistry from the University of Missouri and a Ph.D. in bioinorganic chemistry from Columbia University. Dr. O'Halloran completed his postdoctoral training at MIT.

**Richard P. Van Duyne, Ph.D.** is the Charles E. and Emma H. Morrison Professor of Chemistry at Northwestern University. He discovered surface-enhanced Raman spectroscopy, invented nanosphere lithography and developed localized surface plasmon resonance nanobiosensors. Dr. Van Duyne's research includes surface-enhanced spectroscopy, nanofabrication, nanoparticle optics, combined scanning probe microscopy / Raman microscopy, Raman spectroscopy of mass-selected clusters, ultrahigh vacuum surface science, structure and function of biomolecules on surfaces and nanoparticle optics for chemical and biological sensing. Dr. Van Duyne holds a B.S. in chemistry from Rensselaer Polytechnic Institute and a Ph.D. in analytical chemistry from University of North Carolina at Chapel Hill.

**Holden Thorp, Ph.D.**, was recently named the Chancellor of the University of North Carolina at Chapel Hill where he previously served as the Kenan Professor and Chair of the Chemistry Department. He obtained his B.S. in Chemistry from UNC-Chapel Hill in 1986 where he worked with Professor Thomas J. Meyer. He received his Ph.D. in Chemistry in Professor Harry B. Gray's laboratory at the California Institute of Technology. After postdoctoral research at Yale with Professor Gary Brudvig, he began his independent research career in 1991 and has published over 120 scholarly publications on the electronic properties of DNA and RNA. For his research, Thorp was named a Presidential Young Investigator and has received the Alfred P. Sloan Fellowship, the David and Lucile Packard Fellowship for Science and Engineering and both the New Faculty Award and Teacher-Scholar Award from the Camille and Henry Dreyfus Foundation.

**Robin M. Silva, Esq.**, is currently a Partner at Morgan Lewis. Ms. Silva advises clients on all aspects of patent strategy, with an emphasis on the needs of emerging biotechnology companies, including the creation and management of patent portfolios as well as the evaluation of both client and competitor portfolios, preparation of validity and infringement opinions, and freedom-to-operate opinions. Ms. Silva assists her clients with licensing and strategic collaboration agreements, maximizing portfolio value through the acquisition and exploitation of intellectual property rights. Prior to her employment at Morgan, Ms. Silva worked at Genencor International, a joint venture between Genentech and Corning focused on the industrial applications of protein engineering. Ms. Silva holds a B.S. in Molecular, Cellular and Development Biology from the University of Colorado at Boulder and a J.D. from the University of California, Berkeley College of Law, and has 10 peer-reviewed publications.

---

### **About the Company:**

Ohmx is advancing e-Diagnostics by developing a home monitoring device that quantifies clinical biomarkers and other important disease indicators from the blood of a single finger prick. Ohmx's handheld monitoring device is electronic, low-cost, user-friendly, contains advanced communications protocols, and can be used as a near-patient analyzer in the convenience of the patient's home. Home monitoring of patient's health with Ohmx's devices will allow much more frequent transfer of information to healthcare providers and better healthcare for chronic disease patients than today's paradigm which require a visit to the doctor's office for blood testing.

*This press release may contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.*